Sarepta Therapeutics: Price Target Cut Signals Shift Ahead
Sarepta Therapeutics sees its price target reduced to $38 by Wells Fargo, while still holding an Overweight rating. What does this mean for SRPT investors?
Latest news and analysis for Sarepta Therapeutics (SRPT).
Sarepta Therapeutics sees its price target reduced to $38 by Wells Fargo, while still holding an Overweight rating. What does this mean for SRPT investors?